Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients – Moderna Investor Relations

by

  1. Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients Moderna Investor Relations
  2. Moderna Pops On An FDA Boon For Its Merck-Tied Cancer Vaccine Investor’s Business Daily
  3. Moderna expands CRISPR gene editing research with ElevateBio partnership The Boston Globe
  4. Moderna’s combination skin cancer therapy receives FDA’s breakthrough tag Reuters
  5. Moderna taps Life Edit to develop next-gen gene therapies FierceBiotech
  6. View Full Coverage on Google News

Read original article here

Leave a Comment